Drug Profile


Alternative Names: SKF 106615

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator AnorMED; University of Texas M. D. Anderson Cancer Center
  • Developer Callisto Pharmaceuticals
  • Class Anti-inflammatories; Antirheumatics; Small molecules; Spiro compounds
  • Mechanism of Action Angiogenesis inhibitors; Apoptosis stimulants; Immunomodulators; Interleukin 1 modulators; Interleukin-6 modulators; Macrophage modulators; Osteoclast modulators; Proto oncogene protein c-akt inhibitors; STAT3 transcription factor inhibitors; Tumour necrosis factor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Multiple myeloma; Carcinoid tumour
  • New Molecular Entity No
  • Available For Licensing Yes - Rheumatoid arthritis

Highest Development Phases

  • Discontinued Carcinoid tumour; Inflammation; Multiple myeloma; Osteoporosis; Rheumatoid arthritis; Solid tumours

Most Recent Events

  • 28 Jan 2009 Preclinical trials in Rheumatoid arthritis in USA (PO)
  • 03 Jun 2008 Efficacy and safety data from a phase II trial in Carcinoid tumour presented at the 44th Annual Meeting of the American Society of Clinical Oncology (ASCO-2008)
  • 16 May 2008 Interim efficacy data from a Phase-II trial in Carcinoid tumour released by Callisto Pharmaceuticals
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top